Skip to main content

WaferGen's Revenues, Loss Up In Q3

NEW YORK (GenomeWeb News) – WaferGen Biosystems today reported that its third-quarter revenues rose sharply to $197,951 from $6,700 year over year.
The Fremont, Calif.-based firm posted a net loss of $2.1 million, or $.08 per share, for the three-month period ended Sept. 30, up 24 percent from a net loss of $1.7 million, or $.07 per share, for the third quarter of 2007.
WaferGen’s R&D spending increased around 66 percent to $1.2 million from $728,288, while its SG&A costs declined around 7 percent to $977,255 from $1 million.
Alnoor Shivji, chairman and CEO of WaferGen, said in a statement that the firm is “encouraged by the growing interest in both of our product lines.” WaferGen sells the SmartChip Real-Time PCR System for biomarker discovery and validation and the SmartSlide Micro-Incubation System for stem cell and cell biology research.
The firm finished the quarter with $3.2 million in cash and cash equivalents.
WaferGen said that it has met all the requirements to qualify for the $1 million second tranche of a private placement with the Malaysian Technology Development Corp. and expects to receive the funds “in the near term.”

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.